duncanbucknell.com > Articles > Article Categories

Here you can browse our articles, and filter by category by clicking the links to the left.

Global IP Strategy >Pharma, Biotech
& Chem IP Strategy >IP wars >Strategic Management
of IP >

06.22.2008	Click Time Keywords, sponsored links and IP infringements IP Review, issue 22
06.05.2008	How to prevent and act upon intellectual property rights infringements in China By Danny Friedmann
05.20.2008	Pharmaceutical polymorphs & patent strategy Presentation to GMiA conference, Sydney 21 May 2008
04.18.2008	Quality is the key to a bright patent future (Interview for IAM-Magazine Article) Copy of the article
03.17.2008	The wonderful world of patent drafting Journal of Intellectual Property Law & Practice, Oxford University Press, Vol 3, No.2, Feb 2008
02.06.2008	IP issues are business issues An interview with Jeremy Phillips Mondaq most popular article — February 2008
12.03.2007	Australia's highest court raises the patent invalidity bar Journal of Intellectual Property Law & Practice 2007; doi: 10.1093/jiplp/jpm199
12.03.2007	It's Getting Hotter - Climate Change & IP Strategy Mondaq most popular article — December 2007
10.22.2007	IP Strategy - more than meets the eye In Conversation with Deepak Somaya Mondaq most popular article — November 2007
09.16.2007	Pharmaceutical & Biotech Lifecycle Management (II) How does timing of 1st non-innovator patent affect the period of monopoly for a new drug? Mondaq most popular article — September 2007
09.01.2007	Experimental use and patent infringement in Europe A Review of Trevor Cook's recent Article and Book Journal of Intellectual Property Law & Practice, Oxford University Press, 31 August 2007
08.20.2007	Big Blue Proposes New Type Of Patent Right Published on ipFrontline
08.07.2007	Novartis' Glivec battle with India - patentability of pharmaceutical extension patents Update and brief strategy analysis
08.05.2007	Australia even more patent-friendly after High Court decision IAM-Magazine, August/September 2007, Issue 25
07.17.2007	Pharmaceutical & Biotech Lifecycle Management (I) Are generic's launching earlier than ever? Mondaq most popular article — July 2007
06.22.2007	A scholarly and analytical perspective on the Management of Intellectual Property Journal of Intellectual Property Law & Practice, Oxford University Press, 2007 2(6):419-420
05.23.2007	Australia's Highest Court just made it harder to invalidate patents Lockwood Security Products Pty Ltd v Doric Products Pty Ltd [2007] HCA 21 Published in IP Frontline
05.01.2007	More exceptions to simple rules in IP Strategy (US Supreme Court says no to Extraterritoriality) (Microsoft v AT&T (2007) US Supreme Court)
05.01.2007	In Global IP Disputes - Don’t let your lawyers slavishly apply a legal ‘test’ (KSR v Teleflex (2007) US Sup Crt) Mondaq most popular article — May 2007
04.04.2007	IP freedom to operate put simply™, with the 6T’s™ framework Phase 1 — preparing for and conducting the search
02.08.2007	Multi-country IP disputes in a single court - intriguing but unlikely for now Voda v Cordis (2007) CAFC 05-1238 (1 February 2007)
12.28.2006	In IP Strategy there’s an exception to every simple rule (Eli Lilly and Company v Zenith Goldline and ors (2006), CAFC 05-1396) Mondaq most popular article — January 2007
12.20.2006	Lipitor Australia - unusual grounds invalidate Enantiomer Patent (Ranbaxy Australia Pty Ltd v Warner-Lambert Company LLC(No 2) [2006] FCA 1787
12.07.2006	IP strategy and regulatory controls - you don't have to be sued to get (generic) exclusivity in the US (Zocor returns) (Ranbaxy v Michael O Leavitt, US Court of Appeals for the District of Columbia, 14 Nov. 2006) Mondaq most popular article — December 2006
11.14.2006	IP Due Diligence - put simply™ - with the 6 T’s™ framework Mondaq most popular article — Novermber 2006
10.14.2006	Improper claim dependency invalidates US Lipitor patent Journal of Intellectual Property Law and Practice, Oxford University Press, 2006, 1(12): 748
10.05.2006	Global Litigation Strategy and the art of war Intellectual Asset Management Magazine
09.22.2006	Landmark changes to Australian IP law: (Bolar, wilful infringement, and compulsory license for anti-competitive behaviour)
09.05.2006	BP’s (green) colour mark revoked by Australian Full Court Woolworths Limited v BP plc [2006] FCAFC 132
08.25.2006	Hidden Rembrandts and nascent da Vinci’s - building value by creating and capturing IP
08.16.2006	US Court of Appeal invalidates Lipitor patent due to improper claim dependency (Pfizer Inc. v Ranbaxy Laboratories CAFC 06-1179 (2006))
08.07.2006	Global Brand Strategy & the Top 100 for 2006 (the ‘B.R.A.N.D.I.N.G.’ approach)
07.26.2006	Pharmaceutical taste trade marks - a bitter pill to swallow Strategic points from the US Appeals Board - In re N.V. Organon
07.20.2006	Business method patents — Australian Full Court clarifies patentability Grant v Commissioner of Patents [2006] FCAFC 120
07.17.2006	European intellectual property cat-and-mouse ECJ clarifies jurisdiction in patent disputes
07.13.2006	US product by process patents - Court of Appeal refuses en banc rehearing of SmithKline v Apotex
07.10.2006	The global Lipitor patent battle
07.04.2006	Value for money in global patent litigation relative cost & time to 1st judgment in 8 key jurisdictions
06.23.2006	Pharmaceutical IP Strategy in the US - Merck’s latest tactic for Zocor
06.19.2006	Fosamax once weekly patent invalid on appeal in Australian Full Federal Court
06.14.2006	Analysing IP - put simply Published in IP Frontline
06.07.2006	Canadian Supreme Court allows third party registration of famous mark (‘Barbie’) for dissimilar goods (a restaurant chain) Mattel, Inc. v. 3894207 Canada Inc., 2006 SCC 22 Published in IP Frontline
06.07.2006	Canadian Supreme Court holds ‘Cliquot’ for women’s clothing not likely to cause confusion with ‘Veuve Clicquot’ for luxury Champagne Veuve Clicquot Ponsardin v. Boutiques Cliquot Ltée, 2006 SCC 23 Published in IP Frontline
06.02.2006	Spanish Appellate Court applies Bolar while denying interim injunction in Finasteride decision Merck Sharp & Dohme DE Espana S.A. v Bexal Farmaceutica, S.A; Provincial High Court of Madrid (00089/2006)
05.29.2006	Zocor Generic Exclusivity dispute continues on appeal in the US
05.22.2006	Experts and skilled addressee come to the fore in UK Patents Court Eloxatin decision Mayne Pharma v Debiopharm SA & Sanofi-Synthélabo [2006] EWHC 1123 (Pat)
05.17.2006	European Court of Justice rules SPCs not available for certain combination products
05.16.2006	US Supreme Court reinforces permanent injunction principles in eBay v MercExchange eBay Inc. et al v MercExchange, L.L.C. 547 US_(2006)
05.10.2006	More strategic options for IP owners in the Netherlands
05.08.2006	UK Non-infringement Declarations — an unusual approach
05.05.2006	Australian Federal Court codifies Mareva (‘Freezing’) and Anton Piller (‘Search’) Orders
05.01.2006	Cadbury does not own the colour purple (in Australia, at least) Cadbury Schweppes Pty Ltd v Darrell Lea Chocolate Shops Pty Ltd (No 4) [2006] FCA 446 (27 April 2006) Published in IP Frontline
04.27.2006	Strategic responses to patent trolls
04.26.2006	Commercialization options for technology entrepreneurs - the impact of IP Strategy
04.25.2006	Rambus Wins US$307million in latest round of DRAM patent dispute
04.20.2006	Japanese Grand Panel holds refilled ink cartridges infringed Canon’s patent (Canon Inc. v Recycle Assist Co., Ltd (31 January 2006) IP High Court, Grand Panel)
04.13.2006	US CAFC upholds Aventis Lovenox (enoxaparin) patent enforceability (Aventis Pharma SA v Amphastar Pharmaceuticals [2006] CAFC - 10 April 2006)
04.11.2006	Broad claim scope invalidates UK Nicorandil formulation patent despite ‘powerful arguments’ to the contrary Journal of Intellectual Property Law and Practice, Oxford University Press, 2006, Volume 1, Number 8, p 502
03.30.2006	Spring-boarding to catch up with the rest of the world:
03.10.2006	Australian Full Court reinforces test for obviousness prior art
02.24.2006	CAFC creates another invalidity risk for US process patents
11.02.2005	Australian patent litigation strategy
08.01.2003	‘No automatic defence for non-profit experimental research’